Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Cosimo Martino"'
Autor:
Sara Lonardi, Valter Torri, Fortunato Ciardiello, Andrea Sartore-Bianchi, Salvatore Siena, Silvia Marsoni, Alberto Bardelli, Francesca Bergamo, Cosimo Martino, Elisabetta Fenocchio, Federica Tosi, Silvia Ghezzi, Francesco Leone, Vittorina Zagonel, Andrea Ardizzoni, Alessio Amatu, Katia Bencardino, Emanuele Valtorta, Elena Grassi, Emanuela Bonoldi, Anna Sapino, Angelo Vanzulli, Daniele Regge, Giovanni Cappello, Livio Trusolino
Publikováno v:
ESMO Open, Vol 5, Iss 5 (2020)
Background HER2 is a therapeutic target for metastatic colorectal cancer (mCRC), as demonstrated in the pivotal HERACLES-A (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification) trial with trastuzumab and lapatinib. The aim of HERACLES-B
Externí odkaz:
https://doaj.org/article/83670eb46b49449fab6522df0b311a31
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Autor:
Caterina Vaghi, Emanuela Bonoldi, Emanuele Valtorta, Federica Tosi, Silvia Marsoni, Erika Martinelli, Valter Torri, Alberto Bardelli, Patrizia Racca, Alessio Amatu, Andrea Sartore-Bianchi, Sara Lonardi, Silvia Ghezzi, Giovanna Marrapese, Salvatore Siena, Francesco Leone, Luca Porcu, Vittorina Zagonel, Fortunato Ciardiello, Livio Trusolino, Cosimo Martino, Elisabetta Fenocchio, Beatrice Borelli, Francesca Bergamo
Publikováno v:
The Oncologist
BackgroundHER2 amplification is detected in 3% of patients with colorectal cancer (CRC), making tumors in the metastatic setting vulnerable to double pharmacological HER2 blockade. Preclinical findings show that it also might impair response to anti-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d450fe67f1c3b93024ef25b4c4c384e
https://doi.org/10.1634/theoncologist.2018-0785
https://doi.org/10.1634/theoncologist.2018-0785
Autor:
Giovanni Cappello, Francesca Bergamo, Angelo Vanzulli, Livio Trusolino, Emanuela Bonoldi, Andrea Sartore-Bianchi, Anna Sapino, Katia Bencardino, Salvatore Siena, Sara Lonardi, Cosimo Martino, Francesco Leone, Federica Tosi, Elisabetta Fenocchio, Fortunato Ciardiello, Alberto Bardelli, Silvia Ghezzi, Vittorina Zagonel, Elena Grassi, Alessio Amatu, Silvia Marsoni, Valter Torri, Andrea Ardizzoni, Daniele Regge, Emanuele Valtorta
Publikováno v:
ESMO Open, Vol 5, Iss 5 (2020)
ESMO Open
ESMO Open
open 25 no Background HER2 is a therapeutic target for metastatic colorectal cancer (mCRC), as demonstrated in the pivotal HERACLES-A (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification) trial with trastuzumab and lapatinib. The aim of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06c634e65eec2ca0856f918ad962d27b
https://esmoopen.bmj.com/content/5/5/e000911.full
https://esmoopen.bmj.com/content/5/5/e000911.full
Autor:
Fortunato Ciardiello, Cosimo Martino, Andrea Sartore-Bianchi, Silvia Marsoni, Sara Lonardi, Salvatore Siena, Massimo Aglietta
Publikováno v:
JAMA Oncol
This secondary analysis of data from the HERACLES-A clinical trial examines long-term outcomes in 32 patients with colorectal cancer treated with trastuzumab and lapatinib.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e94e2720e23148033ca5e7ebe793e56
http://hdl.handle.net/11591/432745
http://hdl.handle.net/11591/432745
Autor:
Silvia Marsoni, Giovanni Crisafulli, Rebecca J. Nagy, Salvatore Siena, Erica Bonazzina, Daniele Regge, Emanuele Valtorta, Alice Vanzati, Alessio Amatu, Francesco Leone, Pamela Arcella, Giulia Siravegna, Luca Lazzari, Giorgio Corti, Mariangela Russo, Andrea Cassingena, Andrea Sartore-Bianchi, Monica Montone, Alice Bartolini, Sara Lonardi, Richard B. Lanman, Vittorina Zagonel, Giuseppe Rospo, Stephen R. Fairclough, Antonella Balsamo, Mauro Truini, Annalisa Lorenzato, Federica Di Nicolantonio, Giovanni Cappello, Alberto Bardelli, Andrea Bertotti, Angelo Vanzulli, Francesca Lodi, Cosimo Martino, Benedetta Mussolin, Livio Trusolino, Silvia Ghezzi
Publikováno v:
Cancer Cell
Targeting HER2 is effective in 24% of ERBB2 amplified metastatic colorectal cancer; however, secondary resistance occurs in most of the cases. We studied the evolution of individual metastases during treatment to discover spatially resolved determina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ab8914cf8381ea4fb16c426a0925275
Autor:
Silvia Marsoni, Giovanni Germano, Andrea Sartore Bianchi, Filippo Pietrantonio, Nicola Personeni, Alessio Amatu, Emanuela Bonoldi, Emanuele Valtorta, Ludovic Barault, Federica Di Nicolantonio, Filippo de Braud, Lorenza Rimassa, Armando Santoro, Silvia Ghezzi, Andrea Cassingena, Giovanna Marrapese, Loredana Lupica, Giulia Siravegna, Giuseppe Rospo, Cosimo Martino, Luca Lazzari, Paolo Luraghi, Nabil Amirouchene-Angelozzi, Alberto Bardelli, Salvatore Siena
Publikováno v:
Cancer Research. 79:CT215-CT215
Background. Metastatic colorectal cancer (CRC) remains mostly incurable, with a survival of about two years only. It has been recently proved that CRCs with genetic defects in the mismatch-repair pathway (MMRd), occurring in 15% of early CRC but only
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c221cda338a702979e7e9adf164b7737
https://doi.org/10.1158/1538-7445.am2019-ct215
https://doi.org/10.1158/1538-7445.am2019-ct215
Autor:
Valentina Giannini, Alberto Torresin, Simone Mazzetti, Salvatore Siena, Andrea Sartore-Bianchi, Francesco Leone, Cristina De Mattia, Daniele Regge, Lorenzo Vassallo, Angelo Vanzulli, Silvia Marsoni, Cosimo Martino, Vittorina Zagonel, Giovanni Cappello, Arianna Defeudis
Publikováno v:
Journal of Clinical Oncology. 37:e15086-e15086
e15086 Background: Metastatic Colorectal cancer (mCRC) is the 2nd cause of cancer death worldwide. Repeated cycles of therapies, combined with surgery in oligo-metastatic cases, are the therapeutic standard in mCRC. However, this strategy is seldom r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::573bd796853655b3b6f13040a2c8ca17
https://doi.org/10.1200/jco.2019.37.15_suppl.e15086
https://doi.org/10.1200/jco.2019.37.15_suppl.e15086
Autor:
Andrea Bertotti, Salvatore Siena, Andrea Cassingena, Francesco Leone, Ilaria Depetris, Silvio Veronese, Daniele Regge, Cosimo Martino, Fortunato Ciardiello, Emanuele Valtorta, Erika Martinelli, Paolo M. Comoglio, Valter Torri, Silvia Ghezzi, Katia Bencardino, Giovanna Marrapese, Andrea Sartore-Bianchi, Francesca Bergamo, Vittorina Zagonel, Giulia Siravegna, Patrizia Racca, Sara Lonardi, Livio Trusolino, Silvia Marsoni, Calogero Lauricella, Angelo Vanzulli, Teresa Troiani, Alessio Amatu, Laura Palmeri, Alberto Bardelli
Summary Background We previously found that dual HER2 blockade with trastuzumab and lapatinib led to inhibition of tumour growth in patient-derived xenografts of HER2 -amplified metastatic colorectal cancer. In this study, we aimed to assess the anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98f2bf2129dd70fd29bb4ac774be976b
http://hdl.handle.net/2318/1560696
http://hdl.handle.net/2318/1560696
Autor:
Alice Vanzati, Erica Bonazzina, Cosimo Martino, Salvatore Siena, Giovanni Crisafulli, Francesco Leone, Richard B. Lanman, Giorgio Corti, Andrea Sartore-Bianchi, Sara Lonardi, Mariangela Russo, Livio Trusolino, Vittorina Zagonel, Silvia Ghezzi, Luca Lazzari, Alessio Amatu, Andrea Cassingena, Angelo Vanzulli, Alice Bartolini, Giulia Siravegna, Monica Montone, Benedetta Mussolin, Antonella Balsamo, Silvia Marsoni, Federica Di Nicolantonio, Alberto Bardelli, Francesca Lodi, Pamela Arcella, Daniele Regge, Rebecca Nagy, Emanuele Valtorta, Giovanni Cappello, Mauro Truini, Andrea Bertotti
Publikováno v:
Cancer Research. 78:2848-2848
Targeting HER2 with trastuzumab and lapatinib is effective in ERBB2 amplified metastatic colorectal cancer (mCRC). Although at least 30% of the patients initially respond, secondary resistance occurs in most of the cases. Since the drivers of seconda
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a51e0d6e193ca7f117fc053e81ca851b
https://doi.org/10.1158/1538-7445.am2018-2848
https://doi.org/10.1158/1538-7445.am2018-2848
Autor:
Andrea Cassingena, Giulia Siravegna, Vittorina Zagonel, Andrea Sartore-Bianchi, Sara Lonardi, Justin I. Odegaard, Alessio Amatu, Rebecca J. Nagy, Salvatore Siena, Richard B. Lanman, Francesco Leone, Cosimo Martino, Livio Trusolino, Silvia Marsoni, Benedetta Mussolin, Alberto Bardelli
Publikováno v:
Journal of Clinical Oncology. 36:3506-3506
3506Background: The rate of HER2 (ERBB2) copy number amplification (CNA) in metastatic colorectal cancer (mCRC) ranges from 2-13%. HERACLES, a phase II trial of trastuzumab and lapatinib (T+L) in H...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ed473f72647e1cbbacab0752af6df3e
https://doi.org/10.1200/jco.2018.36.15_suppl.3506
https://doi.org/10.1200/jco.2018.36.15_suppl.3506